Drug: CDX-110 (PF-04948568)
Abstract No.2014Indication: Glioblastoma (brain tumor) Clinical Trial: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM). Presentation Time: Saturday, June 5. Poster session. Notes:Thursday's research abstract reports efficacy results on the first 40 patients enrolled. Twenty-eight of 40 patients, or 70%, are progression free at 5.5 months of follow up. One patient reported a serious hypersensitivity reaction to the CDX-110 injections that required discontinuation from the study. The abstract also states that an additional, placebo-controlled study of CDX-110 will likely be required. Celldex's CDX-110, partnered with Pfizer, is engineered to activate a patient's immune system to fight cancer. Interest in so-called cancer "vaccines" is increasing as Dendreon (DNDN) awaits FDA approval of its prostate cancer immunotherapy Provenge.